Discovery of a Copper-Based Mcl-1 Inhibitor as an Effective Antitumor Agent

Area of Science:

• Medicinal Chemistry
• Cancer Biology
• Pharmacology

Background:

• Myeloid cell leukemia 1 (Mcl-1) is a prosurvival protein crucial for cancer cell survival.
• Targeting Mcl-1 is a promising strategy for cancer therapy, but few effective inhibitors exist.
• Development of novel, potent, and selective Mcl-1 inhibitors is needed.

Purpose of the Study:

• To synthesize and evaluate novel copper complexes as potential Mcl-1 inhibitors.
• To investigate the antitumor activity and mechanism of action of the most promising compound.
• To assess the in vivo efficacy and toxicity of the lead Mcl-1 inhibitor.

Main Methods:

• Preparation of ten copper complexes featuring 9-substituted β-carboline ligands.
• In vitro evaluation of Mcl-1 inhibition and antitumor activity.
• Mechanistic studies involving Mcl-1-Bax/Bak heterodimerization and apoptosis induction.
• In vivo assessment in an NCI-H460 xenograft mouse model.

Main Results:

• Complex 14 emerged as a potent and selective Mcl-1 inhibitor.
• Complex 14 induced Bax/Bak-dependent apoptosis by disrupting Mcl-1-Bax/Bak heterodimerization.
• In vivo studies showed significant tumor growth inhibition, necrosis, and extended survival with no apparent toxicity.

Conclusions:

• Complex 14 is a highly effective copper-based Mcl-1 inhibitor with low toxicity.
• Complex 14 demonstrates significant in vitro and in vivo anticancer efficacy.
• Complex 14 holds potential for the development of new therapies for Mcl-1-dependent cancers.